Director COX CARRIE SMITH acquire 130,000 shares of Selecta Biosciences Inc. [SELB]

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Selecta Biosciences Inc. shares valued at $149,799 were purchased by COX CARRIE SMITH on Jun 13. At $1.15 per share, COX CARRIE SMITH acquired 130,000 shares. The insider’s holdings grew to 212,881 shares worth approximately $0.4 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, BARABE TIMOTHY C purchased 50,000 shares, netting a total of over 38,720 in proceeds. Following the buying of shares at $0.77 each, the insider now holds 250,013 shares.

Before that, Kishimoto Takashi Kei had sold 3,416 shares from its account. In a trade valued at $10,541, the Chief Scientific Officer traded Selecta Biosciences Inc. shares for $3.09 each. Upon closing the transaction, the insider’s holdings decreased to 3,416 shares, worth approximately $0.5 million.

As published in a research note from Needham on June 14, 2022, Selecta Biosciences Inc. [SELB] has been retained to a Buy and the price target has been revised to $5. This represents a 62.4% premium over Thursday’s closing price. Analysts at SVB Leerink started covering the stock with ‘”an Outperform”‘ outlook in a report released in early June. As of June 15, 2021, BTIG Research has initiated its “Buy” rating for SELB. Earlier on January 26, 2021, Mizuho upgraded its rating. Their new recommendation was “a Buy” for SELB stock which previously was a “a Neutral”.

Analyzing SELB’s Price Performance

On Thursday, Selecta Biosciences Inc. [NASDAQ: SELB] rose 13.94% to $1.88. The stock’s lowest price that day was $1.70, but it reached a high of $1.99 in the same session. During the last five days, there has been a surge of approximately 19.75%. Over the course of the year, Selecta Biosciences Inc. shares have dropped approximately -42.33%. Shares of the company reached a 52-week high of $3.3500 on 01/03/22 and a 52-week low of $0.6469 on 05/11/22. A 50-day SMA is recorded $1.3372, while a 200-day SMA reached $2.0361. Nevertheless, trading volume fell to 3.74 million shares from 1.44 million shares the previous day.

Support And Resistance Levels for Selecta Biosciences Inc. (SELB)

According to the 24-hour chart, there is a support level at 1.7233, which, if violated, would cause prices to drop to 1.5667. In the upper region, resistance lies at 2.0133. The next price resistance is at 2.1467. RSI (Relative Strength Index) is 70.58 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0648, which suggests the price will decrease in the coming days. Percent R is at 20.75%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Selecta Biosciences Inc. subject to short interest?

Stocks of Selecta Biosciences Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -2.26 million shares to 6.36 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 8.62 million shares. A decline of -35.53% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.25 of the overall float, the days-to-cover ratio (short ratio) decline to 2.25.

Which companies own the most shares of Selecta Biosciences Inc. (SELB)?

According to BlackRock Fund Advisors filings, the company currently owns 6,157,226 shares, which is about 4.06% of the total SELB shares outstanding. The investor’s shares have plunged by -164,276 from its previous 13-F filing of 6321502.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $7,338,325. Mangrove Partners acquire a 0.02% interest valued at $5.57 million while Invus Public Equities Advisors LL sold a 0 stake. A total of 1,328,432 shares of Selecta Biosciences Inc. were sold by Endurant Capital Management LP during the quarter, and 787,305 were bought by Millennium Management LLC. In its current portfolio, SSgA Funds Management, Inc. holds 1,790,985 shares valued at $2.35 million.

In terms of Selecta Biosciences Inc. share price expectations, FactSet research, analysts set an average price target of $7.29 in the next 12 months, up nearly 324.24% from the previous closing price of $1.65. Analysts anticipate Selecta Biosciences Inc. stock to reach $13.00 by 2022, with the lowest price target being $4.00. In spite of this, 8 analysts ranked Selecta Biosciences Inc. stock as a Buy at the end of 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here